Description

INFA-HEP 25K IU INJ 5ML

Indications

INFA-HEP 25K IU INJ 5ML is primarily indicated for the prevention and treatment of thromboembolic disorders. It is commonly used in patients undergoing major surgical procedures, those with a history of venous thromboembolism, and individuals with certain medical conditions that predispose them to blood clots. Additionally, INFA-HEP is utilized in the management of patients with acute coronary syndromes and in the prevention of clot formation in patients receiving hemodialysis.

Mechanism of Action

INFA-HEP contains the active ingredient Enoxaparin, a low molecular weight heparin (LMWH). Its mechanism of action involves the inhibition of factor Xa and, to a lesser extent, factor IIa (thrombin) in the coagulation cascade. By binding to antithrombin III, Enoxaparin enhances the inactivation of these clotting factors, leading to a reduction in the formation of fibrin clots. This anticoagulant effect helps to prevent the development and progression of thromboembolic events.

Pharmacological Properties

INFA-HEP exhibits several pharmacological properties that make it effective in the prevention and treatment of thromboembolic disorders. It has a predictable pharmacokinetic profile, characterized by a rapid onset of action and a relatively long half-life, allowing for once or twice daily administration. The bioavailability of Enoxaparin is approximately 90%, which is higher than that of unfractionated heparin. The drug is primarily eliminated through the kidneys, necessitating caution in patients with renal impairment.

Contraindications

INFA-HEP is contraindicated in patients with a known hypersensitivity to Enoxaparin or any component of the formulation. It should not be used in individuals with active bleeding disorders, severe thrombocytopenia, or those with a history of heparin-induced thrombocytopenia (HIT). Additionally, caution is advised in patients with conditions that may increase the risk of bleeding, such as peptic ulcer disease or recent intracranial hemorrhage.

Side Effects

Common side effects associated with the use of INFA-HEP include bleeding complications, which can manifest as bruising, hematomas, or more severe hemorrhagic events. Other potential side effects may include injection site reactions, such as pain, redness, or swelling. Less frequently, patients may experience thrombocytopenia or allergic reactions. It is essential for healthcare providers to monitor patients closely for any signs of adverse reactions during treatment.

Dosage and Administration

The dosage of INFA-HEP is determined based on the indication, the patient’s weight, and renal function. For the prevention of thromboembolism in surgical patients, the typical dose is 40 mg administered subcutaneously once daily, starting 2 hours prior to surgery. For the treatment of deep vein thrombosis or pulmonary embolism, the recommended dose is usually 1 mg/kg administered subcutaneously every 12 hours or 1.5 mg/kg once daily. It is crucial to follow the prescribing physician’s guidelines for dosage adjustments, particularly in patients with renal impairment.

Interactions

INFA-HEP may interact with other medications that affect hemostasis, such as antiplatelet agents, nonsteroidal anti-inflammatory drugs (NSAIDs), and other anticoagulants. The concomitant use of these medications can increase the risk of bleeding. Therefore, it is vital for healthcare providers to review a patient’s medication history and monitor for potential interactions. Additionally, patients should be advised to inform their healthcare provider of any new medications they start while receiving INFA-HEP.

Precautions

Before initiating treatment with INFA-HEP, healthcare providers should assess the patient’s risk factors for bleeding and thrombosis. Regular monitoring of platelet counts is recommended, especially in patients with a history of HIT. Patients with renal impairment may require dose adjustments and closer monitoring due to the drug’s renal clearance. Additionally, caution should be exercised in elderly patients, who may have altered pharmacokinetics and increased sensitivity to anticoagulants.

Clinical Studies

Clinical studies have demonstrated the efficacy and safety of INFA-HEP in various populations. In a randomized controlled trial, patients undergoing hip or knee replacement surgery who received Enoxaparin showed a significant reduction in the incidence of venous thromboembolism compared to those receiving placebo. Another study highlighted the effectiveness of INFA-HEP in patients with acute coronary syndrome, where it was associated with improved outcomes compared to unfractionated heparin. These studies support the use of INFA-HEP as a reliable option for anticoagulation therapy.

Conclusion

INFA-HEP 25K IU INJ 5ML is a valuable therapeutic option for the prevention and treatment of thromboembolic disorders. Its low molecular weight heparin formulation provides effective anticoagulation with a favorable safety profile. However, careful consideration of contraindications, potential side effects, and drug interactions is essential for optimal patient management. Ongoing monitoring and patient education are crucial components of therapy to ensure the safe and effective use of INFA-HEP.